Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies. Our valuation framework helps you find stocks with the right balance of growth and value characteristics.
Dermata Therapeutics Inc. (DRMA), a clinical-stage biotherapeutics firm focused on dermatological treatments, is trading at $1.34 as of 2026-04-20, marking a 1.47% decline from the prior trading session’s close. No recent earnings data is available for the firm as of this analysis, so recent price action has been driven primarily by technical factors, broader biotech sector sentiment, and investor positioning around expected future operational updates. This analysis outlines key market context,
Dermata (DRMA) Stock Hot Topic (Institutional Selling) 2026-04-20 - Algo Picks
DRMA - Stock Analysis
3557 Comments
1163 Likes
1
Crickett
Consistent User
2 hours ago
Absolutely top-notch!
👍 212
Reply
2
Marquee
Consistent User
5 hours ago
Indices are maintaining key levels, indicating equilibrium between buyers and sellers.
👍 47
Reply
3
Lachristy
Expert Member
1 day ago
Insightful take on the factors driving market momentum.
👍 236
Reply
4
Maiyah
Daily Reader
1 day ago
Free US stock cash flow analysis and free cash flow yield calculations to identify companies returning value to shareholders. Our cash flow research helps you find companies with the financial flexibility to grow and return capital.
👍 261
Reply
5
Lakeea
Engaged Reader
2 days ago
Clear, concise, and actionable — very helpful.
👍 121
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.